Shares of Hims & Hers Health tumbled 7.2% to $29.47 after the telehealth company reported a second-quarter loss that blindsided Wall Street, raising hard questions about whether its expensive pivot into branded GLP-1 weight-loss treatments will pay off before patience — and cash — run thin. Hims & Hers Revenue Soars 38% but a $0.37 Loss Crushes Expectations — Is the GLP-1 Gamble Worth the Pain
Shares of Hims & Hers Health dropped 7.2% to $29.47 after the telehealth company delivered a quarter that encapsulates its central contradiction: blistering growth on top, deepening losses on the bottom. Revenue rose 40% year-over-year to $753 million, topping estimates, but the company posted a loss of $0.37 per share — wildly missing the expected $0.05 loss. The market's verdict was swift: revenue doesn't matter if you're burning cash to get it.
Selling Brand-Name Drugs Costs a Lot More Than Making Your Own The root cause is structural. After pivoting from selling cheaper, self-compounded weight-loss drugs to brand-name GLP-1 medications through its Novo Nordisk partnership, Hims now operates more as a distributor — yielding lower margins per prescription.
Gross margin cratered to 64% from 76% a year ago, adjusted EBITDA fell to $60.3 million from $82.2 million, and the company swung from a $42.5 million profit to an $86.3 million net loss. That is the price of going legit in GLP-1s.
One-Time Costs Are Piling Up, and They Keep Recurring Management flagged approximately $81 million in non-recurring costs tied to the Eucalyptus acquisition, restructuring, and legal accruals related to FTC litigation. But this follows $33.5 million in restructuring charges and a $15 million legal settlement in Q1. Two straight quarters of massive "one-time" hits test the definition of one-time. Free cash flow was negative $68 million, driven by working-capital demands from the branded weight-loss expansion.
The Growth Story Management Wants You to Focus On The bullish case isn't dead. Domestic revenue rose 16% to $622 million, while international revenue surged more than 17-fold to $131 million.
The company added 300,000 net new subscribers, reaching nearly 3 million.
Management raised full-year revenue guidance to $3.1–$3.3 billion, above the ~$3.0 billion consensus. But revenue guidance without a credible margin recovery timeline is a promissory note, not a catalyst.
When Does the Cash Bleed Stop?
Management acknowledged that gross margins will stay below historical levels near-term, though it projected free cash flow improvement in the second half of 2026 as working capital normalizes.
The company ended Q2 with over $840 million in cash , buying time but not unlimited patience. Investors must decide whether a telehealth platform that deliberately sacrificed its most profitable product line can rebuild profitability fast enough to justify the faith embedded in its stock price.